![](/img/cover-not-exists.png)
5-ASA and acetyl-5-ASA in plasma, urine and faeces from patients with inflammatory bowel disease during 3 g daily (T.I.D. 1 g) dosing off a slow release 5-ASA formulation
T.B. Tjandra-Maga, R. Verbesselt, P. Rutgeerts, G. VantrappenVolume:
183
Year:
1990
Language:
english
Pages:
2385
DOI:
10.1016/0014-2999(90)93949-q
File:
PDF, 235 KB
english, 1990